Related Experiment Video

Updated: Apr 7, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.6K

Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy

Lukas Ruzek1, Tomas Konecny2, Filip Soucek2

  • 1Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota; Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic; Department of Anesthesiology and Intensive Care, St. Anne's University Hospital Brno, Brno, Czech Republic.

The American Journal of Cardiology
|July 5, 2015
PubMed

Insights

Sexual dysfunction (SD) affects 22% of men with hypertrophic cardiomyopathy (HC). Many use phosphodiesterase 5 inhibitors (PDE5i), potentially impacting HC treatment. Further research is needed for safe SD therapy in HC patients.

Area of Science:

  • Cardiology
  • Urology
  • Genetics

Background:

  • Hypertrophic cardiomyopathy (HC) is the most common inherited cardiomyopathy.
  • Sexual dysfunction (SD) is common in cardiovascular disease but its prevalence in HC is unknown.
  • Phosphodiesterase 5 inhibitors (PDE5i), a common SD treatment, may affect the left ventricular outflow tract pressure gradient in HC patients.

Purpose of the Study:

  • To determine the prevalence of sexual dysfunction (SD) in men with hypertrophic cardiomyopathy (HC).
  • To assess the use of phosphodiesterase 5 inhibitors (PDE5i) in men with HC and SD.
  • To highlight the need for evidence-based guidelines for SD treatment in HC.

Main Methods:

  • Retrospective study evaluating medical records of men with HC.
  • SD defined by diagnosis, medication use, or patient-reported symptoms.
  • Prevalence calculated based on identified SD cases.

Main Results:

  • 283 men with HC were evaluated (mean age 52.9 years).
  • 63 patients (22%) were identified with sexual dysfunction (SD).
  • 38% of men with SD were regularly using phosphodiesterase 5 inhibitors (PDE5i).

Conclusions:

  • Sexual dysfunction (SD) and phosphodiesterase 5 inhibitor (PDE5i) use are common in men with hypertrophic cardiomyopathy (HC).
  • Further studies are required to establish safe treatment algorithms for SD in HC.
  • This research addresses a critical gap in managing HC patients with sexual health concerns.

More Related Videos

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease02:21

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

2.0K
Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

14.0K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
749
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
654
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
748
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
670
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
614
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K